IP Library Granted Patent US 7,348,430
Granted Patent B2
US 7,348,430 · App. 11/040,235 · Granted Mar 25, 2008

Production of opioid analgesics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,348,430
App. No.
11/040,235
Granted
Mar 25, 2008
Kind
B2
Abstract

The present invention includes a process for the manufacture of dihydrothebaine, dihydrocodeinone enol acetate, hydrocodone, and analogs thereof by reacting dihydrocodeine or analogs thereof with benzophenone in the presence of potassium tert-alkylate in a hydrocarbon solvent to generate a reaction mixture containing an enolate of the corresponding ketone, followed by addition of the reaction mixture to the electrophilic agent and isolation of the product.

Claims (42)

1. A process for the preparation of a 4,5-epoxymorphinan compound of formula (I)

wherein

R 1 is methyl, substituted methyl or alcohol protecting group;

R 2 is hydrogen, methyl, substituted methyl or amine protecting group,

R 3 is methyl, substituted methyl or alcohol protecting group;

comprising the steps of

(i) reacting an alcohol of formula (II)

wherein R 1 and R 2 are as hereinbefore defined, with benzophenone and potassium tert-alkylate in hydrocarbon solvent to generate a reaction mixture containing the enolate of formula (III)

wherein R 1 and R 2 are as hereinbefore defined; and

(ii) adding reaction mixture containing the enolate of formula (III) to the electrophilic agent of formula (IV)

R 3 X  IV

wherein R 3 is as hereinbefore defined and X is a leaving group, to yield a compound of formula (I), and

(iii) isolating the compound of formula (I).

2. The process of claim 1 , wherein the hydrocarbon solvent is selected from the group consisting of cyclohexane, toluene, heptane and combinations thereof.

3. The process of claim 1 , wherein the potassium tert-alkylate is selected from the group consisting of potassium tert-amylate, potassium tert-butoxide, and combinations thereof.

4. The process of claim 1 , wherein X is a leaving group selected from the group consisting of halide, sulfonate, sulfate, phosphate, phosphite, carboxylate, alkoxyl, and hydroxyl.

5. The process of claim 1 , wherein said compound of formula (I) is a compound of formula IA

wherein R 1 , R 2 , and R 3 are as defined hereinbefore.

6. The process of claim 1 , wherein the molar ratio of said alcohol of formula (II) to said benzophenone is in the range of about 1:3 to about 1:20.

7. The process of claim 6 , wherein the molar ratio of said alcohol of formula (II) to said benzophenone is in the range of about 1:6 to about 1:9.

8. The process of claim 1 , wherein step (i) is performed at a temperature in the range from about 5° C. to about 110° C.

9. The process of claim 8 , which is performed at a temperature in the range from about 15° C. to about 60° C.

10. The process of claim 8 , which is performed at a temperature in the range from about 20° C. to about 50° C.

11. The process of claim 1 , wherein said potassium tert-alkylate is present in an amount from about 1 to about 5 equivalents relative to the amount of said alcohol of formula (II).

12. The process of claim 11 , wherein said potassium tert-alkylate is present in an amount from about 1.4 to about 4 equivalents.

13. The process of claim 1 , wherein said electrophilic agent of formula (IV) is used in step ii in an amount of at least one equivalent relative to the amount of potassium tert-alkylate.

14. The process of claim 1 , wherein said alcohol of formula (II) is dihydrocodeine.

15. The process of claim 14 , wherein said electrophilic agent of formula (IV) in step ii is selected from the group consisting of dimethyl sulfate and acetic anhydride.

16. The process of claim 5 , wherein said compound of formula (IA) is selected from the group consisting of dihydrothebaine and dihydrocodeinone enol acetate.

17. A process for the preparation of a 4,5-epoxymorphinan compound of formula (I)

wherein

R 1 is methyl, substituted methyl or alcohol protecting group;

R 2 is hydrogen, methyl, substituted methyl or amine protecting group,

R 3 is methyl, substituted methyl or alcohol protecting group;

comprising the steps of

(i) reacting an alcohol of formula (II)

wherein R 1 and R 2 are as hereinbefore defined, with benzophenone and potassium tert-alkylate in hydrocarbon solvent to generate a reaction mixture containing the enolate of formula (III)

wherein R 1 and R 2 are as hereinbefore defined; and

(ii) adding the electrophilic agent of formula (IV)

R 3 X  IV

wherein R 3 is as hereinbefore defined and X is a leaving group, to the reaction mixture containing the enolate of formula (III) to yield a compound of formula (I); and

(iii) isolating the compound of formula (I).

Assignments (4)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →